ive been considering running a comparison between these two companies & their respective development trajectories. But had decided not to in the hope that things turned out differently here.But maybe I should.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
